Know Cancer

or
forgot password

Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients


N/A
18 Years
N/A
Open (Enrolling)
Both
Malignant Pleural Mesothelioma

Thank you

Trial Information

Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients


Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor
prognosis. The combination of cisplatin and pemetrexed has recently become the standard of
care in the first-line treatment of MPM. For patients who are unfit to receive a
cisplatin-based chemotherapy, pemetrexed alone [7] or combined with carboplatin [8] has been
proposed as an alternative treatment choice. The identification of molecular predictors of
effective therapy is important for maximizing therapeutic efficacy and minimizing useless
treatment in cancer patients.


Inclusion Criteria:



- Availability of tumor tissue.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line

Outcome Time Frame:

one year

Safety Issue:

No

Principal Investigator

Armando Santoro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Istituto Clinico Humanitas

Authority:

Italy: Ministry of Health

Study ID:

ONC/OSS-04/2008

NCT ID:

NCT00867711

Start Date:

January 2009

Completion Date:

September 2009

Related Keywords:

  • Malignant Pleural Mesothelioma
  • Mesothelioma

Name

Location